SCHEMBL4354314

SCHEMBL4354314

C[C@@H]1OC(c2ccccc2)=N[C@@H]1C(=O)O

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
DRD3 P35462 1/20 0.43
MMP9 P14780 2/20 0.42
USP1 O94782 1/20 0.41
WDR48 Q8TAF3 1/20 0.41
MAOB P27338 4/20 0.38
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 2/20 0.35
KMT2A Q03164 2/20 0.35
HPGD P15428 1/20 0.35
CSNK2A2 P19784 1/20 0.35
CSNK2B P67870 1/20 0.35
CSNK2A1 P68400 1/20 0.35
NPC1 O15118 2/20 0.34
RAB9A P51151 2/20 0.34
MEN1 O00255 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33
ALDH1A1 P00352 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11128470 1.00 DRD2 (0.43) DRD2DRD4DRD3MMP9USP1
SCHEMBL11128460 1.00 DRD2 (0.43) DRD2DRD4DRD3MMP9USP1
SCHEMBL14116701 0.88 MMP9 (0.44) DRD2DRD4DRD3MMP9USP1
SCHEMBL1338758 0.85 KMO (0.40) SMN1; SMN2KDM4EHPGDNPC1RAB9A
SCHEMBL159785 0.84 CYP2D6 (0.41) DRD2DRD4DRD3MMP9USP1
SCHEMBL14116703 0.84 CYP2D6 (0.41) DRD2DRD4DRD3MMP9USP1
SCHEMBL6751629 0.84 CYP2D6 (0.41) DRD2DRD4DRD3MMP9USP1
SCHEMBL231311 0.84 CYP2D6 (0.41) DRD2DRD4DRD3MMP9USP1
SCHEMBL17404616 0.81 HTR2B (0.35) SMN1; SMN2KDM4EKMT2AHPGDNPC1
SCHEMBL15941185 0.81 HTR2B (0.35) SMN1; SMN2KDM4EKMT2AHPGDNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023097407-A1 MODIFIED AMATOXINS AND USES THEREOF THE UNIVERSITY OF BRITISH COLUMBIA (CA) 2023-06-08 WO disclosed
US-10597361-B2 Ethynylbenzene derivatives DUKE UNIVERSITY (US) 2020-03-24 US disclosed
US-20170349544-A1 Ethynylbenzene Derivatives DUKE UNIVERSITY 2017-12-07 US disclosed
US-9738604-B2 Ethynylbenzene derivatives DUKE UNIVERSITY (US) 2017-08-22 US disclosed
US-20130231323-A1 ETHYNYLBENZENE DERIVATIVES DUKE UNIVERSITY (US) 2013-09-05 US disclosed
WO-2012031298-A2 ETHYNYLBENZENE DERIVATIVES DUKE UNIVERSITY (US) 2012-03-08 WO disclosed
US-20090281309-A1 METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) 2009-11-12 US disclosed
EP-1956012-A1 METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE National University Corporation Hokkaido University (JP) 2008-08-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10597361-B2 Ethynylbenzene derivatives Q6ZSR9, EPX, ZYX DRD2 54/4885DRD4 83/4885DRD3 34/4885
US-20170349544-A1 Ethynylbenzene Derivatives Q6ZSR9, EPX, ZYX DRD2 54/4885DRD4 83/4885DRD3 34/4885
US-20090281309-A1 METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE OXA1L, SULT1A1, DAO DRD2 331/4885DRD4 269/4885DRD3 150/4885
US-20130231323-A1 ETHYNYLBENZENE DERIVATIVES Q6ZSR9, EPX, ZYX DRD2 54/4885DRD4 83/4885DRD3 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.